News Sentiment

MENS sentiment intelligence

Jyong Biotech Ltd. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.21 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

88/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.5% over one week, +39.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Doctor shares the ‘most troubling trend’ in men’s health — and why biohacking is to blame

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 88/100 classification
One-week reaction -0.5% Price digesting
Trend fit Trend inactive 39.9% over four weeks
Fair value -88.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 27
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingKey 6
GlobeNewswire 5
TradingView 5
Stock Titan 4
simplywall.st 3
Pluang 2
New York Post 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 8
Capital return 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Investing.com Direct company coverage

Jyong Biotech presents drug candidate at BIO 2026 convention

Jyong Biotech participated in the BIO International Convention, presenting its botanical drug candidate, Botreso (API-1), for benign prostatic hyperplasia. The company is preparing a New Drug Application and pursuing global licensing, actively discussing commercialization with ph

Tone
Positive 65/100
Event
Market update
Published
02 Jul 2026 13:15
Source
Investing.com
Pluang Direct company coverage

Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment.

Jyong Biotech showcased its botanical drug candidate Botreso® at BIO 2026, demonstrating its potential for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms through successful Phase III trials. The company is preparing its New Drug Application and activ

Tone
Positive 87/100
Event
Market update
Published
02 Jul 2026 12:15
Source
Pluang
GlobeNewswire Direct company coverage

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Jyong Biotech showcased its botanical drug portfolio, including its lead candidate Botreso®, at the BIO 2026 International Convention. The company is actively pursuing global licensing discussions for Botreso®, which targets benign prostatic hyperplasia (BPH) and lower urinary tr

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 12:15
Source
GlobeNewswire
Stock Titan Direct company coverage

Jyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026

Jyong Biotech (Nasdaq: MENS) showcased its botanical drug portfolio, including the Phase III candidate Botreso (API-1) for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), at the BIO 2026 International Convention. The company is actively pursuing global

Tone
Positive 71/100
Event
Market update
Published
02 Jul 2026 12:15
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS

This article provides financial information for Jyong Biotech Ltd. (NASDAQ: MENS), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades recorded.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS

This page provides information about the Price to Sales Forward metric for Jyong Biotech Ltd. (NASDAQ: MENS). It confirms that the market is closed, with no trades, and the data is provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS

This article provides financial information for Jyong Biotech Ltd. (NASDAQ:MENS), specifically focusing on its enterprise value to EBIT forward. It indicates available data on this metric, reflecting current financial health and forward-looking valuation.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 18:11
Source
TradingView
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Jyong Biotech Ltd (MENS), covering its support, resistance levels, and various technical indicators. It details individual indicator values like MACD, RSI, and moving averages (MA5, MA10, MA20, MA50, MA100, MA200), offering a summary

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 13:40
Source
TradingKey
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Jyong Biotech Ltd (MENS) dividend and stock split history, indicating that no dividends have been distributed in the past 5 years and no stock splits have occurred. It also presents basic stock information like its current trading price, marke

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Jyong Biotech Ltd (MENS), listing major individual and institutional holders. Key shareholders include Perfect Minds Co Ltd, Laxton Investments Company Ltd, and Linkage Gladden Enterprise Ltd, alongside a breakdown by shareholder

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 16:10
Source
TradingKey
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Jyong Biotech Ltd (MENS), covering its stock performance and various risk metrics. It includes financial data such as market capitalization, daily returns, volatility, and liquidity, but several specific figures are listed as "—" or "0.

Tone
Negative 41/100
Event
Balance sheet
Published
17 Jun 2026 15:42
Source
TradingKey
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Institutional Confidence

This article from TradingKey provides details on the institutional confidence in Jyong Biotech Ltd (MENS), listing key shareholders and their holdings. The stock closed at $1.590 with a minor dip and has a market cap of $121.64M. The institutional shareholding data shows several

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Jyong Biotech Ltd (MENS), detailing its current stock price, market cap, and trading performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. The article serves as a bri

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 16:40
Source
TradingKey
www.marketscreener.com Direct company coverage

Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.

Certain ordinary shares of Jyong Biotech Ltd. are under a lock-up agreement set to expire on June 16, 2026. This lock-up period, starting from June 16, 2025, affects directors, officers, and holders of more than 5% of outstanding shares for 365 days, while holders of less than 5%

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 02:10
Source
www.marketscreener.com
ChartMill Direct company coverage

JYONG BIOTECH LTD (MENS) Stock Chart

The article provides a stock chart for JYONG BIOTECH LTD (MENS), listed on NASDAQ. As of June 9, 2026, at 01:23 PM, the stock price was 1.85 USD, down 0.15 (-7.5%). The page offers various tools and data for stock analysis.

Tone
Negative 31/100
Event
Market update
Published
05 Jun 2026 17:39
Source
ChartMill
Finviz Direct company coverage

MENS - Jyong Biotech Ltd Stock Price and Quote

This article provides detailed stock information for Jyong Biotech Ltd (MENS), including its last closing price, financial metrics, performance indicators, and recent news announcements. It covers key data such as market capitalization, P/E ratios, employee count, and details abo

Tone
Positive 64/100
Event
Market update
Published
30 May 2026 14:39
Source
Finviz
Pluang Direct company coverage

Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia.

Jyong Biotech's CEO, Fu-Feng Kuo, detailed the company's strategy to secure FDA approval for Botreso®, a botanical drug for benign prostatic hyperplasia (BPH) affecting over 12 million men in the US. The company has completed pivotal studies, showing a strong safety profile, and

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 May 2026 13:39
Source
Pluang
GlobeNewswire Direct company coverage

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Jyong Biotech's CEO, Ms. Fu-Feng Kuo, detailed the company's FDA pathway and global strategy in a PharmaBoardroom interview. The company is developing plant-derived therapeutics, notably Botreso® for benign prostatic hyperplasia (BPH), and emphasizes a strong focus on the U.S. ma

Tone
Positive 72/100
Event
Market update
Published
29 May 2026 12:00
Source
GlobeNewswire
Stock Titan Direct company coverage

12M Americans have BPH; one biotech is testing a plant-based option

Jyong Biotech is advancing Botreso, a plant-based drug targeting benign prostatic hyperplasia (BPH) with 12.2 million US patients, and a prostate cancer prevention asset, PCP. The company highlighted its FDA pathway, which includes additional US studies, aiming for a combined NDA

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 11:59
Source
Stock Titan
Simply Wall Street Direct company coverage

Jyong Biotech (Nasdaq:MENS) - Stock Analysis

Jyong Biotech (Nasdaq:MENS) is a science-driven biotechnology company developing plant-derived drugs for urinary system diseases. The company reported a delayed 20-F filing and provided updates on its botanical drugs, Botreso, PCP (MCS-8), and MCS-2, highlighting their clinical e

Tone
Positive 72/100
Event
Market update
Published
28 May 2026 12:39
Source
Simply Wall Street
Quiver Quantitative Direct company coverage

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025

Jyong Biotech Ltd. announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC on May 14, 2026. The Taiwan-based biotechnology company specializes in developing plant-derived therapeutics for urinary system diseases and o

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 12:44
Source
Quiver Quantitative
Stock Titan Direct company coverage

Inside Jyong Biotech's 2025 SEC annual report filing for investors

Jyong Biotech (Nasdaq: MENS) announced the filing of its Form 20-F annual report for the fiscal year ended December 31, 2025, with the SEC on May 14, 2026. The report is accessible on the company’s investor relations site and the SEC website, detailing key financial figures like

Tone
Positive 65/100
Event
Market update
Published
15 May 2026 12:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Ltd. announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on May 14, 2026. The report is accessible on the company's investor relations website and the SEC's website, with har

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 12:39
Source
GlobeNewswire